Application of inulin/Eudragit RS in 5-ASA pellet coating with tuned, sustained-release feature in an animal model of ulcerative colitis

A tunable release of 5-aminosalicylic acid (5-ASA) could bring therapeutic benefits in the treatment of inflammatory bowel disease (IBD). A 3(2) factorial design was used to achieve a tuned delivery of 5 ASA pellets in the small and large intestine using a coating composed of inulin/Eudragit RS (RS). The ratio of inulin/RS and coating level were independent variables while the dependent variables were the percent of drug release at pH 1.2 in 2 h and total release of drug in 10 h at pH 6.8. 5 ASA release from pellets was examined at different pH levels and the therapeutic efficacy of the optimum pellets was compared to 5 ASA pellets of Pentasa in rats with ulcerative colitis. The inulin/RS of 18/82 at a coating level of 16% was found to be the optimum for delivery of the drug to the small and large intestine. The coated pellets offered a superior therapeutic outcome compared to uncoated pellets and Pentasa in terms of colitis activity index (CAI), and the colon's tissue enzymes of GSH and MDA. The optimum coating composed of inulin and RS could offer a tuned sustained release of 5 ASA throughout the small and large intestine with the sensitivity of drug release to microbial degradation.

Automated summary

The study demonstrated that a coating composed of inulin and RS can achieve a tuned release of 5-ASA pellets in the small and large intestine, offering potential therapeutic benefits for IBD. The optimized ratio of inulin/RS at 18/82 with a coating level of 16% resulted in the best delivery of the drug to the intestines.